Human IL-1B Beta Monoclonal Antibody
Produktgrößen
1 mg
£268,00
YR0006-1MG
5 mg
£746,00
YR0006-5MG
20 mg
£1442,00
YR0006-20MG
Über dieses Produkt
- SKU:
- YR0006
- Zusätzliche Namen:
- IL-1|IL1-BETA|IL1B|IL1beta|IL1F2
- Anwendung:
- Block/Inhibit/Neutralise, Cell-based/Functional Assay, ELISA
- Klonalität:
- Monoclonal
- Weitere Details:
- Canakinumab is a recombinant human monoclonal antibody which binds to IL-1B Beta (interleukin-1 beta). It's mode of action is based on the neutralization of IL-1B Beta signaling, resulting in suppression of inflammation in patients with disorders of autoimmune origin. In June 2009, the FDA approved canakinumab for the treatment of cryopyrin-associated periodic syndromes (CAPS), a spectrum of autoinflammatory syndromes. In September 2016, the FDA approved it's use for three additional rare and serious auto-inflammatory diseases: tumor necrosis factor receptor associated periodic syndrome (TRAPS),hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), and familial Mediterranean fever (FMF). In June 2020, canakinumab was FDA-approved for the indication to treat active Still's disease, including adult-onset Still's disease (AOSD).
- Formulierung:
- Purified from cell culture supernatant in an animal-free facility
- Immunogen:
- IL-1β
- Isotyp:
- IgG1, kappa
- Molekulargewicht:
- 150 kDa
- Reinheit:
- >95%
- Versandbedingungen:
- Blue Ice
- Lagerbedingungen:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Hersteller:
- ABclonal Technology
- Typ:
- Antibody: Biosimilar Antibody
- Datenblatt des Herstellers:YR0006